Prenatal depression and selective serotonin reuptake inhibitors

International Journal of Neuroscience

Volumn 120, Issue 3, 2010, Pages 163-167

  Field, Tiffany ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FIELDING GRADUATE UNIVERSITY   (United States)

Author keywords

Alternative therapies; Antidepressants exposure; Prenatal depression

Indexed keywords

CITALOPRAM; FLUOXETINE; PAXOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; FETUS; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HUMAN; NERVE CELL DIFFERENTIATION; NEWBORN; PREGNANT WOMAN; PRENATAL EXPOSURE; PRENATAL PERIOD; REVIEW; SECOND TRIMESTER PREGNANCY;

CONTROL GROUPS; DEPRESSION; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 77950799172     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207450802338697     Document Type: Review

References (27)

1. Bellantuono, C., Migliarese, G., & Imperadore, G. (2006). Pharmacologic therapy of depression during pregnancy. Recenti Progressi in Medicina, 97, 94-107.
2. Berard, A., Ramos, E., Rey, E., Blais, L., St-Andre, M., & Oraichi, D. (2007). First trimester exposure to paroxetine and risk of cardiac malformations in infants:The importance of dosage. BirthDefects Research and Developmental Reproduction Toxicology, 80, 18-27.
3. Carper, R., Fleisher, B., Lee-Ancajas, J., et al. (2003). Follow-up of children of depressed mothers exposed or not to antidepressants drugs during pregnancy. Journal of Pediatrics, 142, 402-408.
4. Chambers, C., Hernandez-Diaz, S., Van Marter, L., Werler, M., Louik, C., Jones, K., et al. (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. The New England Journal of Medicine, 354, 579-587. (Pubitemid 43209105)
5. Cohen, L., Altshuler, L., Harlow, B., Nonacs, R., Newport, D., Viguera, A., et al. (2006). Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA, 295, 499-507. (Pubitemid 43200344)
6. Cohen, L., Heller, V., Bailey, J., Grush, L., Ablon, J., & Bouffard, S. (2000). Birth outcomes following prenatal exposure to fluoxetine. Biology and Psychiatry, 48, 996-1000.
7. Cooper, L., Gonzalez, J., Gallo, J., Rost, K., Meredith, L., Rubenstein, L., et al.. (2003). The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Medical Care, 41, 479-489.
8. Costei, A., Kozer, E., Ho, T., Ito, S., & Koren, G. (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatric and Adolescent Medicine, 156, 1129-1132.
9. DeCeballos, M., Benedi, A., Urdin, C., & Del Rio, J. (1985). Prenatal exposure of rats to antidepressant drugs down-regulates beta-adenoceptors and 5-HT2 receptors in cerebral cortex: Lack of correlation between 5-HT2 receptors and serotonin-mediated behavior. Neuropharmacology, 24, 947-952.
10. Dieter, J., Field, T., Hernandez-Reif,M., Jones, N. A., Lecanuet, J. P., Salman, F. A., et al.. (2001). Maternal depression and increased fetal activity. Journal of Obstetrics and Gynaecology, 21, 468-473.
11. Einarson, T., & Einarson, A. (2005). Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiology Drugs and Safety, 14, 823-827.
12. Field, T., Hernandez-Reif,M., Diego, M., Schanberg, S., & Kuhn, C. (2005). Cortisol decreases and serotonin and dopamine increase following massage therapy. International Journal of Neuroscience, 115, 1397-1413. (Pubitemid 41291417)
13. Gentile, S. (2007). Serotonin reuptake inhibitor-induced perinatal complications. Pediatric Drugs, 9, 97-106.
14. Hendrick, V., Smith, L., Suri, R.,Hwang, S., Haynes, D., & Altshuler, L. (2003). Birth outcomes after prenatal exposure to antidepressant medication. American Journal of Obstetrics and Gynecology, 188, 812-815.
15. Laine, K., Heikkinen, T., Ekblad, U., & Kero, P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin condentrations. Archives of General Psychiatry, 60, 720-726.
16. Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L., & Klinger, G. (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatrics and Adolescent Medicine, 160, 173-176.
17. Malm, H., Klaukka, T., & Neuvonen, P. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology, 106, 1289-1296.
18. Marcus, S., Flynn, H., Blow, F., & Barry, K. (2003) Depressive symptoms among pregnant women screened in obstetrics settings. Journal of Women's Health, 12, 373-380.
19. Marcus, S., Flynn, H., Blow, F., & Barry, K. (2005). A screening study of antidepressant treatment rates and mood symptoms in pregnancy. Archives of Women Mental Health, 8, 25-27.
20. Moses-Kolko, E., Bogen, D., Perel, J., Bregar, A., Uhl, K., Levin, B., et al. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JournalOf The American Medical Association, 293, 2372-2383. (Pubitemid 40676760)
21. Newport, D., & Stowe, Z. (2003). Clinical management of perinatal depression: Focus on paroxetine. Psychopharmacology Bulletin, 1, 148-166.
22. Oberlander, T., Misri, S., Fitzgerald, C., Kostaras, X., Rurak, D., & Riggs, W. (2004). Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Journal of Clinical Psychiatry, 65, 230-237.
23. Oberlander, T.,Warburton,W., Misri, S., Aghajanian, J., & Hertzman, C. (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry, 63, 898-906.
24. Sleath, B., West, S., Tudor, G., Perreira, K., King V., & Morrissey, J. (2005). Ethnicity and depression treatment preferences of pregnant women. Journal of Psychosomatic Obstetrics and Gynecology, 26, 135-140.
25. Thormahlen, G. (2006). Paroxetine use during pregnancy: Is it safe? Annual Pharmacotherapy, 40, 1834-1837.
26. Vorhees, C., Acuff-Smitt, K., Schilling, M., Fisher, J., Moran, M., & Buelke-Sam, J. (1994). A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology, 23, 194-205. (Pubitemid 24277242)
27. Zeskind, P., & Stephens, L. (2006).Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics, 113, 368-375.